Literature DB >> 31738337

Route of Oseltamivir Administration Affects Metabolite Concentrations in Critically Ill Children.

Sonya C Tang Girdwood1,2, Tomoyuki Mizuno2,3, Kelli A Krallman4, Laura A Benken4, Erin M Stoneman4, Toni M Yunger4, Hector R Wong3,4, Alexander A Vinks2,3, Jennifer M Kaplan3,4.   

Abstract

We performed a prospective cohort study to investigate oseltamivir administration in critically ill children. We found that enteric tube administration of oseltamivir resulted in lower concentrations of its active metabolite compared with oral delivery. These findings could have significant clinical implications, and more studies are required to better understand the effects of administration route on potential lower systemic metabolite exposure.

Entities:  

Year:  2019        PMID： 31738337      PMCID： PMC7023915          DOI： 10.1097/INF.0000000000002473

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  9 in total

1.  MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.

Authors:  J H Proost; D K Meijer
Journal:  Comput Biol Med       Date:  1992-05       Impact factor: 4.589

2.  Characteristics and Outcomes of Young Children Hospitalized With Laboratory-confirmed Influenza or Respiratory Syncytial Virus in Ontario, Canada, 2009-2014.

Authors:  Sarah A Buchan; Hannah Chung; Timothy Karnauchow; J Dayre McNally; Michael A Campitelli; Jonathan B Gubbay; Kevin Katz; Allison J McGeer; David C Richardson; Susan E Richardson; Andrew Simor; Marek Smieja; George Zahariadis; Dat Tran; Natasha S Crowcroft; Laura C Rosella; Jeffrey C Kwong
Journal:  Pediatr Infect Dis J       Date:  2019-04       Impact factor: 2.129

Review 3.  Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Authors:  G He; J Massarella; P Ward
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

4.  Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.

Authors:  C Oo; J Barrett; G Hill; J Mann; A Dorr; R Dutkowski; P Ward
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

5.  High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.

Authors:  Carole Giraud; Sandra Manceau; Mehdi Oualha; Hélène Chappuy; Agnès Mogenet; Patrick Duchêne; Sarah Ducrocq; Philippe Hubert; Jean M Treluyer
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

6.  Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support.

Authors:  Enno D Wildschut; Matthijs de Hoog; Maurice J Ahsman; Dick Tibboel; Albert D M E Osterhaus; Pieter L A Fraaij
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

7.  Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.

Authors:  Jian Yang; Deshi Shi; Dongfang Yang; Xiulong Song; Bingfang Yan
Journal:  Mol Pharmacol       Date:  2007-05-30       Impact factor: 4.436

8.  Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.

Authors:  Mohamed A Kamal; Scott A Van Wart; Craig R Rayner; Vishak Subramoney; Daniel K Reynolds; Catharine C Bulik; Patrick F Smith; Sujata M Bhavnani; Paul G Ambrose; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

9.  Neuraminidase inhibitors for critically ill children with influenza.

Authors:  Janice K Louie; Samuel Yang; Michael C Samuel; Timothy M Uyeki; Robert Schechter
Journal:  Pediatrics       Date:  2013-11-25       Impact factor: 7.124
  9 in total
  2 in total

1.  Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19.

Authors:  Kei Irie; Atsushi Nakagawa; Hirotoshi Fujita; Ryo Tamura; Masaaki Eto; Hiroaki Ikesue; Nobuyuki Muroi; Keisuke Tomii; Tohru Hashida
Journal:  Clin Transl Sci       Date:  2020-06-29       Impact factor: 4.689

2.  Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of β-Lactam Antibiotics in Critically Ill Children.

Authors:  Sonya C Tang Girdwood; Peter H Tang; Mark E Murphy; Andrea R Chamberlain; Laura A Benken; Rhonda L Jones; Erin M Stoneman; Jennifer M Kaplan; Alexander A Vinks
Journal:  J Clin Pharmacol       Date:  2020-10-27       Impact factor: 3.126
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.